Cannabidiol (CBD) is a non-psychoactive component of marijuana that does not activate cannabinoid receptors but may inhibit the degradation of the endocannabinoid anandamide. A study found that elevated anandamide levels in cerebrospinal fluid were inversely correlated with psychotic symptoms in schizophrenia. In a double-blind, randomized clinical trial, CBD was compared with amisulpride, a potent antipsychotic, in patients with acute schizophrenia. Both treatments were safe and led to significant clinical improvement, but CBD had a better side-effect profile. CBD treatment was associated with increased serum anandamide levels, which correlated with clinical improvement. These results suggest that inhibiting anandamide degradation may contribute to CBD's antipsychotic effects, potentially offering a new mechanism for treating schizophrenia. The study also found that CBD reduced extrapyramidal symptoms, weight gain, and prolactin levels compared to amisulpride. CBD did not significantly affect hepatic or cardiac functions and was well-tolerated. The study supports the idea that CBD may be as effective as amisulpride in treating schizophrenia, with a better safety profile. The findings suggest that CBD's ability to inhibit FAAH activity and enhance anandamide signaling may be a key mechanism in its antipsychotic effects. Further research is needed to confirm this link.Cannabidiol (CBD) is a non-psychoactive component of marijuana that does not activate cannabinoid receptors but may inhibit the degradation of the endocannabinoid anandamide. A study found that elevated anandamide levels in cerebrospinal fluid were inversely correlated with psychotic symptoms in schizophrenia. In a double-blind, randomized clinical trial, CBD was compared with amisulpride, a potent antipsychotic, in patients with acute schizophrenia. Both treatments were safe and led to significant clinical improvement, but CBD had a better side-effect profile. CBD treatment was associated with increased serum anandamide levels, which correlated with clinical improvement. These results suggest that inhibiting anandamide degradation may contribute to CBD's antipsychotic effects, potentially offering a new mechanism for treating schizophrenia. The study also found that CBD reduced extrapyramidal symptoms, weight gain, and prolactin levels compared to amisulpride. CBD did not significantly affect hepatic or cardiac functions and was well-tolerated. The study supports the idea that CBD may be as effective as amisulpride in treating schizophrenia, with a better safety profile. The findings suggest that CBD's ability to inhibit FAAH activity and enhance anandamide signaling may be a key mechanism in its antipsychotic effects. Further research is needed to confirm this link.